evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

25 questions · 25 findings · 2 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2 · 8%GRADE not reported 0 · 0%Very low 3 · 12%Low 17 · 68%Moderate 3 · 12%High 0 · 0%

Alemtuzumab 12 mg vs interferon beta‐1a

Number of participants with new or enlarging T2‐hyperintense lesions on MRI · adults with relapsing–remitting multiple sclerosis

The review found no eligible studies for this question.

1 finding from 1 review

Alemtuzumab 12 mg vs interferon beta‐1a

Dropout · adults with relapsing–remitting multiple sclerosis

It is very uncertain whether alemtuzumab 12 mg changes dropouts Assessed by: number of participants who dropped out compared with interferon beta‐1a (very low certainty).

1 finding from 1 review

Alemtuzumab 24 mg vs interferon beta‐1a

Proportion of participants with relapse‐free survival at ≥ 12 months · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

Alemtuzumab 24 mg may leads to lower relapse‐free survival compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Alemtuzumab 24 mg vs interferon beta‐1a

Sustained disease progression‐free survival · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

Alemtuzumab 24 mg may leads to lower sustained disease progression‐free survival compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Alemtuzumab 24 mg vs interferon beta‐1a

Adverse events, including serious adverse events Assessed by: number of participants with ≥ 1 event · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

Alemtuzumab 24 mg showed no clear difference in adverse events, including serious adverse events Assessed by: number… compared with interferon beta‐1a (low certainty).

1 finding from 1 review